Primary outcomes of the placebo-controlled phase 2 study PERSEUS (NCT01360840) investigating two dose regimens of abituzumab (DI17E6, EMD 525797) in the treatment of chemotherapy-naive patients (pts) with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC).
Maha Hussain
Research Funding - Merck KGaA
Kurt Miller
Consultant or Advisory Role - Merck
Honoraria - Merck
Ilona Rybicka
Employment or Leadership Position - Merck KGaA
Rolf Bruns
Employment or Leadership Position - Merck KGaA